Literature DB >> 14644181

Recent improvements in antigene technology.

Sabrina Buchini1, Christian J Leumann.   

Abstract

DNA triple-helix-based approaches to control and modulate cellular functions on the level of genomic DNA (antigene technology) suffered in the past from a stepmother-like treatment in comparison to the flourishing field of oligonucleotide-based control of translation (antisense technology). This was mostly due to lack of affinity of triplex-forming oligonucleotides to their DNA target, to sequence restriction constraints imposed by the triple helical recognition motifs and by open questions to the accessibility of the target DNA. Recent developments in the area have brought about new bases that specifically recognize pyrimidine-purine inversion sites as well as sugar modifications, for example, the 2'-aminoethoxy-oligonucleotides or oligonucleotides based on the locked nucleic acid sugar unit, which greatly enhance triplex stability and alleviate in part the sequence restriction constraints. With this, sequence-specific genomic DNA manipulation is starting to become a useful tool in biotechnology.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14644181     DOI: 10.1016/j.cbpa.2003.10.007

Source DB:  PubMed          Journal:  Curr Opin Chem Biol        ISSN: 1367-5931            Impact factor:   8.822


  16 in total

1.  Recognition of double-stranded RNA by guanidine-modified peptide nucleic acids.

Authors:  Pankaj Gupta; Oluwatoyosi Muse; Eriks Rozners
Journal:  Biochemistry       Date:  2011-12-20       Impact factor: 3.162

2.  Solution structure of a dsDNA:LNA triplex.

Authors:  Jesper J Sørensen; Jakob T Nielsen; Michael Petersen
Journal:  Nucleic Acids Res       Date:  2004-11-18       Impact factor: 16.971

3.  A gold nanoparticle based approach for screening triplex DNA binders.

Authors:  Min Su Han; Abigail K R Lytton-Jean; Chad A Mirkin
Journal:  J Am Chem Soc       Date:  2006-04-19       Impact factor: 15.419

4.  Short peptide nucleic acids bind strongly to homopurine tract of double helical RNA at pH 5.5.

Authors:  Ming Li; Thomas Zengeya; Eriks Rozners
Journal:  J Am Chem Soc       Date:  2010-06-30       Impact factor: 15.419

Review 5.  Perspectives on conformationally constrained peptide nucleic acid (PNA): insights into the structural design, properties and applications.

Authors:  Chaturong Suparpprom; Tirayut Vilaivan
Journal:  RSC Chem Biol       Date:  2022-03-18

6.  Orientation preferences of backbone secondary amide functional groups in peptide nucleic acid complexes: quantum chemical calculations reveal an intrinsic preference of cationic D-amino acid-based chiral PNA analogues for the P-form.

Authors:  Christopher M Topham; Jeremy C Smith
Journal:  Biophys J       Date:  2006-10-27       Impact factor: 4.033

Review 7.  Tailored therapeutics based on 1,2,3-1H-triazoles: a mini review.

Authors:  Parteek Prasher; Mousmee Sharma
Journal:  Medchemcomm       Date:  2019-05-14       Impact factor: 3.597

8.  Insights into the DNA stabilizing contributions of a bicyclic cytosine analogue: crystal structures of DNA duplexes containing 7,8-dihydropyrido [2,3-d]pyrimidin-2-one.

Authors:  Ella Czarina Magat Juan; Satoru Shimizu; Xiao Ma; Taizo Kurose; Tsuyoshi Haraguchi; Fang Zhang; Masaru Tsunoda; Akihiro Ohkubo; Mitsuo Sekine; Takayuki Shibata; Christopher L Millington; David M Williams; Akio Takénaka
Journal:  Nucleic Acids Res       Date:  2010-06-16       Impact factor: 16.971

9.  Developing a programmed restriction endonuclease for highly specific DNA cleavage.

Authors:  Kristin Eisenschmidt; Thomas Lanio; András Simoncsits; Albert Jeltsch; Vera Pingoud; Wolfgang Wende; Alfred Pingoud
Journal:  Nucleic Acids Res       Date:  2005-12-14       Impact factor: 16.971

10.  Discovery of novel triple helical DNA intercalators by an integrated virtual and actual screening platform.

Authors:  Patrick A Holt; Patricia Ragazzon; Lucjan Strekowski; Jonathan B Chaires; John O Trent
Journal:  Nucleic Acids Res       Date:  2009-01-09       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.